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LETTERS
Lessons from a 
Special Service for 
Public Health,  
Brazil 
To the Editor: Many thanks for 
your interesting and informative spe-
cial section on infectious diseases in 
the Amazon  Region  (1).  Your  read-
ers should also be interested in a little 
known, but extremely successful, sus-
tainable  health  program  that  had  its 
start in the Amazon.
In 1942, the governments of Brazil 
and the United States agreed to estab-
lish a special service for public health 
(called the Serviço Especial de Saúde 
Pública). The purpose of this program 
was to improve health conditions in 
key areas in the Amazon, expedite the 
collection and export of native rubber, 
and counteract the growing influence 
of  Nazi  Germany  in  Latin  America 
(2). The program spread to the Vale do 
Rio Doce, where there were resources 
of iron ore, mica, and optical quartz, 
which were important for the war ef-
fort. Although the program eventually 
moved to all states of Brazil, the Ama-
zon  program  remained  an  important 
activity  for  ≈50  years  before  it  was 
integrated into the Brazilian Ministry 
of Health (3).
The program in the Amazon fo-
cused primarily on infectious disease. 
It comprised programs of immuniza-
tion,  provision  of  small  sustainable 
water systems, development of privy 
programs (sewer systems in the larger 
centers  of  population),  malaria  con-
trol,  improvement  of  residences  and 
living conditions for Chagas disease 
control,  epidemiologic  intelligence, 
and  extensive  training  for  auxiliary 
and professional personnel.
The  effects  of  this  program  are 
shown by the increase in life expectan-
cy for all age groups, with an increase 
of >10 years for those childhood age 
groups  for  whom  infectious  disease 
control would have the greatest effect 
from  1939–1941  to  1950–1951  (4). 
This program contains many lessons 
for the planners of health and disease 
control  projects  in  tropical,  low-in-
come countries.
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To  the  Editor:  Nontyphoidal 
salmonellosis (NTS) is a major food-
borne  illness  worldwide.  Extended-
spectrum  cephalosporins  (ESCs)  are 
currently preferred drugs for treatment 
of children with NTS. However, resis-
tance to ESCs has emerged worldwide 
and has become a serious public health 
problem. This resistance is caused by 
production of various class A extend-
ed-spectrum  β-lactamases  (ESBLs) 
and class C cephalosporinases in Sal-
monella enterica (1).
National  surveillance  systems, 
ideally  based  on  integration  of  data 
for  animals,  food,  and  humans,  are 
needed to develop strategies for con-
taining antimicrobial drug resistance. 
Such systems are primarily based on 
a network of public or private clinical 
laboratories that refer Salmonella iso-
lates to public health laboratories for 
identification. However, this laborato-
ry-based surveillance system in devel-
oping countries is hampered by cost 
constraints  and  poor  access  to  qual-
ity health facilities, resulting in a low 
rate of isolation of bacterial pathogens 
from patients having mild infections. 
These constraints account for the lack 
of  data  and  underestimation  of  the 
number of NTS cases in many coun-
tries, including Morocco.
According to the World Health Or-
ganization Global Salm Surv database 
(www.who.int/salmsurv/activities/ 
en), the Moroccan National Institute 
of Hygiene reported only 210 human 
non-Typhi  isolates  and  999  animal 
non-Gallinarum isolates during 1999–
2003.  Antimicrobial  drug  resistance 
data are extremely rare. We report the 
presence of nontyphoidal Salmonella 
isolates  resistant  to  ESCs  during  an 
outbreak  of  food  poisoning  and  in 
food products in Morocco.
In  March  2008,  an  S.  enterica 
serotype Typhimurium strain was iso-
lated from stool samples of 45 persons 
who had attended a wedding ceremo-
ny  in  Errachidia.  Clinical  symptoms   
were  diarrhea,  vomiting,  and  stom-
ach  cramps,  beginning  24–72  hours 
after these persons had eaten a tagine 
prepared  with  poorly  cooked  broiler 
chickens. Five patients were hospital-
ized for 3 days, but no deaths were re-
corded. S. enterica serotype Typhimu-
rium was isolated from leftovers of a 
broiler carcass stored in a refrigerator.
PulseNet  (http://pulsenetinter 
national.org/pulsenet/pulsenet.asp) 
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standard pulsed-field gel electropho-
resis (PFGE) of XbaI-digested chro-
mosomal  DNA  showed  that  human 
and  poultry  isolates  had  identical 
profiles. Antimicrobial drug suscep-
tibility  was  determined  by  the  disk 
diffusion method and E-tests, as de-
scribed (2). Isolates were resistant to 
penicillins and ceftazidime but were 
susceptible  to  other  antimicrobial 
drug classes tested. A positive dou-
ble-disk synergy test result suggested 
that these strains produced an ESBL. 
Isolates showed higher levels of resis-
tance to ceftazidime (MIC 128 mg/L) 
than to ceftriaxone (MIC 8 mg/L).
For  identification  of  the  ESBL 
gene,  we  conducted  PCR  amplifica-
tions  of  blaTEM,  blaSHV,  and  blaCTX-M 
group  genes,  as  described  (3).  Only 
the  SHV  amplicon  was  obtained, 
and  DNA  sequencing  showed  this 
amplicon  to  be  100%  identical  to 
blaSHV-12. Resistance to ESCs and the 
blaSHV-12  gene  were  transferred  into 
Escherichia  coli  by  conjugation. An 
≈60-kb plasmid was isolated from E. 
coli  transconjugants  and  the  paren-
tal strain. PCR-based replicon typing 
analysis identified replicon IncI1 (4). 
Although the broilers had been reared 
locally,  no  environmental  investiga-
tion was conducted.
In November 2007, an S. enter-
ica serotype Newport strain was iso-
lated from a pastry made with locally 
produced eggs during a food survey 
conducted in southern Morocco. The 
isolate was resistant to penicillins, ce-
foxitin (MIC 128 mg/L), ceftriaxone 
(MIC 64 mg/L), ceftazidime (MIC 128 
mg/L),  streptomycin,  sulfonamides, 
chloramphenicol, and tetracycline. We 
identified the blaCMY-2 gene carried by 
a  210-kb  nonconjugative  plasmid  of 
replicon IncA/C. These CMY-2–pro-
ducing isolates are also known as Sal-
monella  Newport  multidrug-resistant 
(MDR)–AmpC.  XbaI-PFGE  showed 
a profile similar to the New8a profile 
described in 2003 in France during a 
small outbreak linked to consumption 
of imported horse meat (2).
ESC-resistant Salmonella isolates 
have  been  reported  in  Morocco  (5). 
This report described a serotype Typh-
imurium clone that produced TEM-3 
that  was  isolated  from  10  children 
hospitalized  in  Casablanca  in  1994. 
Few studies have been conducted on 
ESC-resistant S. enterica in northern 
Africa, and most have reported hospi-
tal-acquired infections (1). Our study 
identified  ESC-resistant  Salmonella 
strains in the human food chain and in 
poultry for human consumption in Mo-
rocco. Salmonella isolates resistant to 
ESCs were not identified in food dur-
ing 2002–2005 at the Institut Pasteur 
de  Casablanca  (104  Salmonella  iso-
lates from 11,516 food samples) (6). 
Emergence in poultry and humans of 
an MDR serotype Keurmassar strain 
that produced SHV-12 was reported in 
Senegal in 2001 (7). 
Although CMY-2 was originally 
identified  in  a  serotype  Senftenberg 
isolate from a child in Algeria (8), we 
report the Salmonella Newport MDR-
AmpC  strain  in  Africa.  Salmonella 
Newport  MDR-AmpC  isolates  were 
reported in 1998 in the United States 
(9), where they quickly spread to cattle 
and humans. Recent potential spread 
of this strain into poultry in the United 
States was suggested by Varma et al. 
(10). Because of the risk for spread-
ing, an efficient national antimicrobial 
drug resistance monitoring system for 
foodborne  pathogens  in  Morocco  is 
required to prevent dissemination of 
bacterial strains resistant to first-line 
antimicrobial drugs in humans.
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Group B  
Streptococcus  
Meningitis in Child 
with Cochlear  
Implant
To  the  Editor:  Streptococcus   
agalactiae, designated group B strepto-
coccus (GBS), is a major cause of in-
fections in neonates and young infants 
(1). Invasive GBS disease in children 
beyond infancy is uncommon, occur-
ring  mainly  as  bacteremia  without  a 
focus;  meningitis  caused  by  GBS  is 
rarely  reported  (2).  Cochlear  implant 
recipients  have  been  documented  as 
having a higher rate of postimplantation 
bacterial meningitis than a cohort of the 
same age in the general US population 
(3). However, no cochlear implant re-
cipient described has been reported to 
be infected with GBS. We report a case 
of GBS meningitis in a 6-year-old boy 
with a cochlear implant.
The  patient  was  hospitalized  in 
2007  with  a  1-day  history  of  fever, 
headache,  and  vomiting.  His  medi-
cal history indicated congenital bilat-
eral  deafness  diagnosed  at  1  month 
of age and consistent with Patterson 
syndrome (i.e., unusual facies, deaf-
ness,  bronzed  hyperpigmentation  of 
the  skin,  cutis  laxa,  mental  retarda-
tion, and bony deformities) (4). At 4 
years of age, he received a right-ear 
cochlear implant with good functional 
result.  Preoperative  high-resolution 
computed tomography of the tempo-
ral  bones  showed  bilateral  inner  ear 
malformations  of  both  the  cochlear 
and  vestibular  labyrinth,  conditions 
consistent with bilateral Mondini de-
formity (5). Mastoids and middle ears 
were well aerated. No evidence of ce-
rebrospinal fluid leak appeared during 
physical examination or imaging. He 
received a dose of 23-valent pneumo-
coccal polysaccharide vaccine.
At  the  time  of  hospital  admis-
sion, he was somnolent but could be 
aroused and was cooperative. He had 
nuchal  rigidity,  dysmorphic  facies, 
and  oligodactyly.  Fundi,  skin,  and 
ears were unremarkable on examina-
tion. Lumbar puncture showed a total 
protein level of 204 mg/dL, a glucose 
level of 1.6 mmol/L (blood glucose 3 
mmol/L), and 4,800 leukocytes/mm3 
with  88%  neutrophils;  no  bacteria 
were seen on the Gram stain. Blood 
count  was  remarkable  for  leukocy-
tosis  of  30,000/mm3  and  neutrophil 
predominance.
The  patient  received  treatment 
with  dexamethasone,  vancomycin, 
and  ceftriaxone;  after  treatment,  his 
condition  improved  rapidly.  Blood 
culture was sterile, but GBS grew in 
the  cerebrospinal  fluid  culture  (the 
isolate  being  resistant  only  to  tetra-
cycline). Therapy was continued with 
ampicillin for 3 weeks. Repeated test-
ing of his hearing and speech percep-
tion with the cochlear implant showed 
no deterioration.
GBS plays a major role in early- 
and late-onset infections in neonates 
and  young  infants  (1).  Infections  in 
older children and adults have been de-
scribed, especially in elderly patients 
or those suffering from chronic condi-
tions such as diabetes mellitus, malig-
nancy, or HIV infection (6). A review 
of  medical  records  of  patients  with 
GBS infections over a 7-year period 
at a children’s hospital in Memphis, 
Tennessee, USA, showed that, among 
18 patients >3 months of age (13% of 
all GBS infections in the study), bac-
teremia was most commonly reported; 
3 cases of ventriculo-peritoneal shunt 
infections were recorded, but no cases 
of meningitis without foreign devices 
were  found  (2).  GBS  meningitis  in 
children beyond infancy is rare; only a 
few cases have been reported (7).
Cochlear  implantation  is  the 
standard  treatment  for  children  and 
adults affected by severe and severe-
to-profound  sensorineural  hearing 
loss. The implant is a neural stimula-
tor with an electrode array surgically 
placed near the auditory nerve fibers 
in the scala tympani of the cochlea. 
Pediatric  cochlear  implant  recipients 
were  found  to  be  at  higher  risk  for 
developing  bacterial  meningitis  than 
children in the general US population 
(3). Increased risk was evident in the 
perioperative period but extended to 
>2  years  postimplantation  (8).  Most 
meningitis cases were associated with 
an implant with a positioner, a silastic 
wedge inserted next to the implanted 
electrode in the cochlea to position the 
electrode closer to the cochlear nerve 
endings  and  thus  facilitate  electrical 
signal transmission. Most of those in-
fections were caused by Streptococcus 
pneumoniae, and none by GBS (3,8). 
In our patient, the implant did not in-
clude a positioner. The timing of men-
ingitis was consistent with the timing 
indicated in previous reports, but the 
infecting organism was unique.
Inner  ear  malformations  them-
selves  are  associated  with  increased 
risk  for  meningitis  (9).  The  patient 
reported here had bilateral inner ear 
malformations;  therefore,  estimating 
the relative role of the deformity com-
pared with the cochlear implant’s role 
in  the  pathogenesis  of  meningitis  in 
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